1
|
Cirilli M, Maroni A, Moutaharrik S, Foppoli A, Ochoa E, Palugan L, Gazzaniga A, Cerea M. Organ-Retentive Osmotically Driven System (ORODS): A Novel Expandable Platform for in Situ Drug Delivery. Int J Pharm 2023; 644:123295. [PMID: 37544386 DOI: 10.1016/j.ijpharm.2023.123295] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2023] [Revised: 08/02/2023] [Accepted: 08/03/2023] [Indexed: 08/08/2023]
Abstract
Drug delivery systems capable of being retained within hollow organs allow the entire drug dose to be delivered locally to the disease site or to absorption windows for improved systemic bioavailability. A novel Organ-Retentive Osmotically Driven System (ORODS) was here proposed, obtained by assembling drug-containing units having prolonged release kinetics with osmotic units used as increasing volume compartments. Particularly, prototypes having H-shape design were conceived, manufactured and evaluated. Such devices were assembled by manually inserting a tube made of regenerated cellulose (osmotic unit) into the holes of two perforated hydrophilic tableted matrices containing paracetamol as a tracer drug. The osmotic unit was obtained by folding and gluing a plain regenerated cellulose membrane and loading sodium chloride inside. When immersed in aqueous fluids, this compartment expanded to approximately 80% of its maximum volume within 30 min of testing, and a plateau was maintained for about 6 h. Subsequently, it slowly shrank to approximately 20% of the maximum volume in 24 h, which would allow for physiological emptying of the device from hollow organs. While expanding, the osmotic unit acquired stiffness. Drug release from H-shaped ORODSs conveyed in hard-gelatin capsules was shown to be prolonged for more than 24 h.
Collapse
Affiliation(s)
- Micol Cirilli
- Università degli Studi di Milano, Department of Pharmaceutical Sciences, Via G. Colombo 71, 20133 Milan, Italy
| | - Alessandra Maroni
- Università degli Studi di Milano, Department of Pharmaceutical Sciences, Via G. Colombo 71, 20133 Milan, Italy
| | - Saliha Moutaharrik
- Università degli Studi di Milano, Department of Pharmaceutical Sciences, Via G. Colombo 71, 20133 Milan, Italy.
| | - Anastasia Foppoli
- Università degli Studi di Milano, Department of Pharmaceutical Sciences, Via G. Colombo 71, 20133 Milan, Italy
| | - Evelyn Ochoa
- Università degli Studi di Milano-Bicocca, Department of Biotechnology and Bioscience, Piazza della Scienza 2, 20126 Milan, Italy
| | - Luca Palugan
- Università degli Studi di Milano, Department of Pharmaceutical Sciences, Via G. Colombo 71, 20133 Milan, Italy
| | - Andrea Gazzaniga
- Università degli Studi di Milano, Department of Pharmaceutical Sciences, Via G. Colombo 71, 20133 Milan, Italy
| | - Matteo Cerea
- Università degli Studi di Milano, Department of Pharmaceutical Sciences, Via G. Colombo 71, 20133 Milan, Italy
| |
Collapse
|
2
|
Staniszewska M, Romański M, Polak S, Garbacz G, Dobosz J, Myslitska D, Romanova S, Paszkowska J, Danielak D. A Rational Approach to Predicting Immediate Release Formulation Behavior in Multiple Gastric Motility Patterns: A Combination of a Biorelevant Apparatus, Design of Experiments, and Machine Learning. Pharmaceutics 2023; 15:2056. [PMID: 37631270 PMCID: PMC10458881 DOI: 10.3390/pharmaceutics15082056] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2023] [Revised: 07/24/2023] [Accepted: 07/28/2023] [Indexed: 08/27/2023] Open
Abstract
Gastric mechanical stress often impacts drug dissolution from solid oral dosage forms, but in vitro experiments cannot recreate the substantial variability of gastric motility in a reasonable time. This study, for the first time, combines a novel dissolution apparatus with the design of experiments (DoE) and machine learning (ML) to overcome this obstacle. The workflow involves the testing of soft gelatin capsules in a set of fasted-state biorelevant dissolution experiments created with DoE. The dissolution results are used by an ML algorithm to build the classification model of the capsule's opening in response to intragastric stress (IS) within the physiological space of timing and magnitude. Next, a random forest algorithm is used to model the further drug dissolution. The predictive power of the two ML models is verified with independent dissolution tests, and they outperform a polynomial-based DoE model. Moreover, the developed tool reasonably simulates over 50 dissolution profiles under varying IS conditions. Hence, we prove that our method can be utilized for the simulation of dissolution profiles related to the multiplicity of individual gastric motility patterns. In perspective, the developed workflow can improve virtual bioequivalence trials and the patient-centric development of immediate-release oral dosage forms.
Collapse
Affiliation(s)
- Marcela Staniszewska
- Physiolution Polska, 74 Piłsudskiego St., 50-020 Wrocław, Poland; (G.G.); (J.D.); (D.M.); (S.R.); (J.P.)
| | - Michał Romański
- Department of Physical Pharmacy and Pharmacokinetics, Poznan University of Medical Sciences, 3 Rokietnicka St., 60-806 Poznań, Poland; (M.R.); (D.D.)
| | - Sebastian Polak
- Faculty of Pharmacy, Medical College, Jagiellonian University, Medyczna 9 Street, 30-688 Kraków, Poland;
| | - Grzegorz Garbacz
- Physiolution Polska, 74 Piłsudskiego St., 50-020 Wrocław, Poland; (G.G.); (J.D.); (D.M.); (S.R.); (J.P.)
| | - Justyna Dobosz
- Physiolution Polska, 74 Piłsudskiego St., 50-020 Wrocław, Poland; (G.G.); (J.D.); (D.M.); (S.R.); (J.P.)
| | - Daria Myslitska
- Physiolution Polska, 74 Piłsudskiego St., 50-020 Wrocław, Poland; (G.G.); (J.D.); (D.M.); (S.R.); (J.P.)
| | - Svitlana Romanova
- Physiolution Polska, 74 Piłsudskiego St., 50-020 Wrocław, Poland; (G.G.); (J.D.); (D.M.); (S.R.); (J.P.)
| | - Jadwiga Paszkowska
- Physiolution Polska, 74 Piłsudskiego St., 50-020 Wrocław, Poland; (G.G.); (J.D.); (D.M.); (S.R.); (J.P.)
| | - Dorota Danielak
- Department of Physical Pharmacy and Pharmacokinetics, Poznan University of Medical Sciences, 3 Rokietnicka St., 60-806 Poznań, Poland; (M.R.); (D.D.)
| |
Collapse
|
3
|
Application of In Vivo Imaging Techniques and Diagnostic Tools in Oral Drug Delivery Research. Pharmaceutics 2022; 14:pharmaceutics14040801. [PMID: 35456635 PMCID: PMC9025904 DOI: 10.3390/pharmaceutics14040801] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2022] [Revised: 03/25/2022] [Accepted: 03/27/2022] [Indexed: 02/04/2023] Open
Abstract
Drug absorption following oral administration is determined by complex and dynamic interactions between gastrointestinal (GI) physiology, the drug, and its formulation. Since many of these interactions are not fully understood, the COST action on “Understanding Gastrointestinal Absorption-related Processes (UNGAP)” was initiated in 2017, with the aim to improve the current comprehension of intestinal drug absorption and foster future developments in this field. In this regard, in vivo techniques used for the characterization of human GI physiology and the intraluminal behavior of orally administered dosage forms in the GI tract are fundamental to gaining deeper mechanistic understanding of the interplay between human GI physiology and drug product performance. In this review, the potential applications, advantages, and limitations of the most important in vivo techniques relevant to oral biopharmaceutics are presented from the perspectives of different research fields.
Collapse
|
4
|
Lex TR, Rodriguez JD, Zhang L, Jiang W, Gao Z. Development of In Vitro Dissolution Testing Methods to Simulate Fed Conditions for Immediate Release Solid Oral Dosage Forms. AAPS J 2022; 24:40. [PMID: 35277760 DOI: 10.1208/s12248-022-00690-5] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2021] [Accepted: 02/10/2022] [Indexed: 11/30/2022] Open
Abstract
In vitro dissolution testing is widely used to mimic and predict in vivo performance of oral drug products in the gastrointestinal (GI) tract. This literature review assesses the current in vitro dissolution methodologies being employed to simulate and predict in vivo drug dissolution under fasted and fed conditions, with emphasis on immediate release (IR) solid oral dosage forms. Notable human GI physiological conditions under fasted and fed states have been reviewed and summarized. Literature results showed that dissolution media, mechanical forces, and transit times are key dissolution test parameters for simulating specific postprandial conditions. A number of biorelevant systems, including the fed stomach model (FSM), GastroDuo device, dynamic gastric model (DGM), simulated gastrointestinal tract models (TIM), and the human gastric simulator (HGS), have been developed to mimic the postprandial state of the stomach. While these models have assisted in expanding physiological relevance of in vitro dissolution tests, in general, these models lack the ability to fully replicate physiological conditions/processes. Furthermore, the translatability of in vitro data to an in vivo system remains challenging. Additionally, physiologically based pharmacokinetic (PBPK) modeling has been employed to evaluate the effect of food on drug bioavailability and bioequivalence. Here, we assess the current status of in vitro dissolution methodologies and absorption PBPK modeling approaches to identify knowledge gaps and facilitate further development of in vitro dissolution methods that factor in fasted and fed states. Prediction of in vivo drug performance under fasted and fed conditions via in vitro dissolution testing and modeling may potentially help efforts in harmonizing global regulatory recommendations regarding in vivo fasted and fed bioequivalence studies for solid oral IR products.
Collapse
Affiliation(s)
- Timothy R Lex
- Division of Complex Drug Analysis, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, St. Louis, Missouri, 63110, USA
| | - Jason D Rodriguez
- Division of Complex Drug Analysis, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, St. Louis, Missouri, 63110, USA
| | - Lei Zhang
- Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, 20993, USA
| | - Wenlei Jiang
- Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, 20993, USA.
| | - Zongming Gao
- Division of Complex Drug Analysis, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, St. Louis, Missouri, 63110, USA.
| |
Collapse
|
5
|
Neumann M, Heimhardt C, Seidlitz K, Koziolek M, Schneider F, Schiller C, Hanke U, Anschütz M, Knopke C, Donath F, Thoma R, Brätter C, Schug B, Franke H, Weitschies W. Development of a furosemide-containing expandable system for gastric retention. J Control Release 2021; 338:105-118. [PMID: 34416321 DOI: 10.1016/j.jconrel.2021.08.026] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2021] [Revised: 07/28/2021] [Accepted: 08/16/2021] [Indexed: 10/20/2022]
Abstract
More than 50 years ago, the first gastroretentive dosage forms came up. Since then, no practical and at the same time reliable gastroretentive system is available on market. A major obstacle in the development of novel gastroretentive systems is the lack of proper predictive test methods. In the present work, we aimed at developing and fully characterizing an expandable gastroretentive system containing furosemide as model drug. On the one hand, we used well-established in vitro tests for drug dissolution and gastroretentive properties (paddle apparatus, swelling characteristics). On the other hand, we used two novel models (dissolution stress test device, mechanical antrum model) to assess these properties under biorelevant conditions. Moreover, we performed an in vivo study under fed and fasted conditions that combined blood sampling and a high-resolution imaging technique (magnetic marker monitoring) to determine gastrointestinal location with the assessment of a pharmacodynamic endpoint (urinary sodium excretion). In vitro dissolution tests confirmed prolonged drug release over more than 8 h independent from pH and with slight pressure sensitivity. Swelling studies indicated good swelling behavior within 4 h along with medium gastroretentive properties as determined with the mechanical antrum model. In vivo imaging showed prolonged gastric residence time after fed compared to fasted administration (481 min vs 38 min). Comparison of geometric means of AUCo-tlast of the model drug confirmed this observation with 10 times higher value after fed administration. Urinary excretion of sodium well reflected the increased sodium-reuptake inhibition due to higher furosemide exposure under fed conditions. However, the poor performance after fasted intake of the system is in line with data from several other gastroretentive formulations. The present study highlighted the value of novel test methods during the development of gastroretentive formulations. Yet, a system with reproducible gastroretentive properties especially under fasted conditions has to be designed.
Collapse
Affiliation(s)
- Marco Neumann
- Institute of Pharmacy, Department of Biopharmaceutics & Pharmaceutical Technology, Center of Drug Absorption and Transport, University of Greifswald, Felix-Hausdorff-Str. 3, 17487 Greifswald, Germany
| | - Claudia Heimhardt
- Institute of Pharmacy, Department of Biopharmaceutics & Pharmaceutical Technology, Center of Drug Absorption and Transport, University of Greifswald, Felix-Hausdorff-Str. 3, 17487 Greifswald, Germany
| | - Knut Seidlitz
- LTS Lohmann Therapie Systeme AG, LTS Lohmann Therapie-Systeme AG, Lohmannstr. 2, D-56626 Andernach, Germany
| | - Mirko Koziolek
- Institute of Pharmacy, Department of Biopharmaceutics & Pharmaceutical Technology, Center of Drug Absorption and Transport, University of Greifswald, Felix-Hausdorff-Str. 3, 17487 Greifswald, Germany
| | - Felix Schneider
- Institute of Pharmacy, Department of Biopharmaceutics & Pharmaceutical Technology, Center of Drug Absorption and Transport, University of Greifswald, Felix-Hausdorff-Str. 3, 17487 Greifswald, Germany
| | - Christiane Schiller
- LTS Lohmann Therapie Systeme AG, LTS Lohmann Therapie-Systeme AG, Lohmannstr. 2, D-56626 Andernach, Germany
| | - Ulrike Hanke
- LTS Lohmann Therapie Systeme AG, LTS Lohmann Therapie-Systeme AG, Lohmannstr. 2, D-56626 Andernach, Germany
| | | | | | - Frank Donath
- SocraTec R&D, Im Setzling 35, 61440 Oberursel, Germany
| | - Rudy Thoma
- Formula GmbH, Grenzallee 305b, 14167 Berlin, Germany
| | | | - Barbara Schug
- SocraTec R&D, Im Setzling 35, 61440 Oberursel, Germany
| | - Hanshermann Franke
- LTS Lohmann Therapie Systeme AG, LTS Lohmann Therapie-Systeme AG, Lohmannstr. 2, D-56626 Andernach, Germany
| | - Werner Weitschies
- Institute of Pharmacy, Department of Biopharmaceutics & Pharmaceutical Technology, Center of Drug Absorption and Transport, University of Greifswald, Felix-Hausdorff-Str. 3, 17487 Greifswald, Germany.
| |
Collapse
|
6
|
Weitschies W, Müller L, Grimm M, Koziolek M. Ingestible devices for studying the gastrointestinal physiology and their application in oral biopharmaceutics. Adv Drug Deliv Rev 2021; 176:113853. [PMID: 34192551 DOI: 10.1016/j.addr.2021.113853] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2021] [Revised: 06/22/2021] [Accepted: 06/23/2021] [Indexed: 12/17/2022]
Abstract
Ingestible sensor systems are unique tools for obtaining physiological data from an undisturbed gastrointestinal tract. Since their dimensions correspond to monolithic oral dosage forms, such as enteric coated tablets or hydrogel matrix tablets, they also allow insights into the physiological conditions experienced by non-disintegrating dosage forms on their way through the gastrointestinal tract. In this work, the different ingestible sensor systems which can be used for this purpose are described and their potential applications as well as difficulties and pitfalls with respect to their use are presented. It is also highlighted how the data on transit times, pH, temperature and pressure as well as the data from different animal models commonly used in drug product development such as dogs and pigs have contributed to a deeper mechanistic understanding of oral drug delivery.
Collapse
Affiliation(s)
- Werner Weitschies
- Institute of Pharmacy, Center of Drug Absorption and Transport, University of Greifswald, Greifswald, Germany.
| | - Laura Müller
- Institute of Pharmacy, Center of Drug Absorption and Transport, University of Greifswald, Greifswald, Germany
| | - Michael Grimm
- Institute of Pharmacy, Center of Drug Absorption and Transport, University of Greifswald, Greifswald, Germany
| | - Mirko Koziolek
- NCE Formulation Sciences, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany
| |
Collapse
|
7
|
Juszczyk E, Kisło K, Żero P, Tratkiewicz E, Wieczorek M, Paszkowska J, Banach G, Wiater M, Hoc D, Garbacz G, Sczodrok J, Danielak D. Development and Bio-Predictive Evaluation of Biopharmaceutical Properties of Sustained-Release Tablets with a Novel GPR40 Agonist for a First-in-Human Clinical Trial. Pharmaceutics 2021; 13:804. [PMID: 34071286 PMCID: PMC8227174 DOI: 10.3390/pharmaceutics13060804] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2021] [Revised: 05/20/2021] [Accepted: 05/25/2021] [Indexed: 11/17/2022] Open
Abstract
Sustained-release (SR) formulations may appear advantageous in first-in-human (FIH) study of innovative medicines. The newly developed SR matrix tablets require prolonged maintenance of API concentration in plasma and should be reliably assessed for the risk of uncontrolled release of the drug. In the present study, we describe the development of a robust SR matrix tablet with a novel G-protein-coupled receptor 40 (GPR40) agonist for first-in-human studies and introduce a general workflow for the successful development of SR formulations for innovative APIs. The hydrophilic matrix tablets containing the labeled API dose of 5, 30, or 120 mg were evaluated with several methods: standard USP II dissolution, bio-predictive dissolution tests, and the texture and matrix formation analysis. The standard dissolution tests allowed preselection of the prototypes with the targeted dissolution rate, while the subsequent studies in physiologically relevant conditions revealed unwanted and potentially harmful effects, such as dose dumping under an increased mechanical agitation. The developed formulations were exceptionally robust toward the mechanical and physicochemical conditions of the bio-predictive tests and assured a comparable drug delivery rate regardless of the prandial state and dose labeled. In conclusion, the introduced development strategy, when implemented into the development cycle of SR formulations with innovative APIs, may allow not only to reduce the risk of formulation-related failure of phase I clinical trial but also effectively and timely provide safe and reliable medicines for patients in the trial and their further therapy.
Collapse
Affiliation(s)
- Ewelina Juszczyk
- Research and Development Center, Celon Pharma S.A., Marymoncka 15, 05-052 Kazuń Nowy, Poland; (E.J.); (K.K.); (P.Ż.); (E.T.); (M.W.)
| | - Kamil Kisło
- Research and Development Center, Celon Pharma S.A., Marymoncka 15, 05-052 Kazuń Nowy, Poland; (E.J.); (K.K.); (P.Ż.); (E.T.); (M.W.)
| | - Paweł Żero
- Research and Development Center, Celon Pharma S.A., Marymoncka 15, 05-052 Kazuń Nowy, Poland; (E.J.); (K.K.); (P.Ż.); (E.T.); (M.W.)
| | - Ewa Tratkiewicz
- Research and Development Center, Celon Pharma S.A., Marymoncka 15, 05-052 Kazuń Nowy, Poland; (E.J.); (K.K.); (P.Ż.); (E.T.); (M.W.)
| | - Maciej Wieczorek
- Research and Development Center, Celon Pharma S.A., Marymoncka 15, 05-052 Kazuń Nowy, Poland; (E.J.); (K.K.); (P.Ż.); (E.T.); (M.W.)
| | - Jadwiga Paszkowska
- Physiolution Polska sp. z o.o., 74 Piłsudskiego St., 50-020 Wrocław, Poland; (J.P.); (G.B.); (M.W.); (D.H.); (G.G.)
| | - Grzegorz Banach
- Physiolution Polska sp. z o.o., 74 Piłsudskiego St., 50-020 Wrocław, Poland; (J.P.); (G.B.); (M.W.); (D.H.); (G.G.)
| | - Marcela Wiater
- Physiolution Polska sp. z o.o., 74 Piłsudskiego St., 50-020 Wrocław, Poland; (J.P.); (G.B.); (M.W.); (D.H.); (G.G.)
| | - Dagmara Hoc
- Physiolution Polska sp. z o.o., 74 Piłsudskiego St., 50-020 Wrocław, Poland; (J.P.); (G.B.); (M.W.); (D.H.); (G.G.)
| | - Grzegorz Garbacz
- Physiolution Polska sp. z o.o., 74 Piłsudskiego St., 50-020 Wrocław, Poland; (J.P.); (G.B.); (M.W.); (D.H.); (G.G.)
- Physiolution GmbH, Walther Rathenau Strasse 49a, 17489 Greifswald, Germany;
| | - Jaroslaw Sczodrok
- Physiolution GmbH, Walther Rathenau Strasse 49a, 17489 Greifswald, Germany;
| | - Dorota Danielak
- Department of Physical Pharmacy and Pharmacokinetics, Poznan University of Medical Sciences, 6 Święcickiego St., 60-781 Poznań, Poland
| |
Collapse
|
8
|
Hofsäss MA, Dressman J. Suitability of the z-Factor for Dissolution Simulation of Solid Oral Dosage Forms: Potential Pitfalls and Refinements. J Pharm Sci 2020; 109:2735-2745. [DOI: 10.1016/j.xphs.2020.05.019] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2020] [Revised: 05/04/2020] [Accepted: 05/08/2020] [Indexed: 12/21/2022]
|
9
|
Hofsäss MA, Dressman J. Evaluation of Differences in Dosage Form Performance of Generics Using BCS-Based Biowaiver Specifications and Biopharmaceutical Modeling–Case Examples Amoxicillin and Doxycycline. J Pharm Sci 2020; 109:2437-2453. [DOI: 10.1016/j.xphs.2020.04.011] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2020] [Revised: 04/06/2020] [Accepted: 04/17/2020] [Indexed: 12/12/2022]
|
10
|
Six years of progress in the oral biopharmaceutics area – A summary from the IMI OrBiTo project. Eur J Pharm Biopharm 2020; 152:236-247. [DOI: 10.1016/j.ejpb.2020.05.008] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2019] [Accepted: 05/10/2020] [Indexed: 12/18/2022]
|
11
|
Hens B, Masuy I, Deloose E, Mols R, Tack J, Augustijns P. Exploring the impact of real-life dosing conditions on intraluminal and systemic concentrations of atazanavir in parallel with gastric motility recording in healthy subjects. Eur J Pharm Biopharm 2020; 150:66-76. [PMID: 32113916 DOI: 10.1016/j.ejpb.2020.02.014] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2019] [Revised: 02/21/2020] [Accepted: 02/25/2020] [Indexed: 02/07/2023]
Abstract
This work strived to explore gastrointestinal (GI) dissolution, supersaturation and precipitation of the weakly basic drug atazanavir in humans under different 'real-life' intake conditions. The impact of GI pH and motility on these processes was thoroughly explored. In a cross-over study, atazanavir (Reyataz®) was orally administered to 5 healthy subjects with (i) a glass of water, (ii) a glass of Coca-Cola® and (iii) a glass of water under hypochlorhydric conditions (induced by concomitant intake of a proton-pump inhibitor (PPI)). After intake, GI fluids were aspirated from the stomach and the duodenum and, subsequently, analyzed for atazanavir. In parallel, blood samples were collected to assess systemic concentrations. In general, the results of this study revealed that the acidic gastric pH in combination with gastric residence time played a crucial role in the dissolution of atazanavir along the GI tract. After intake of atazanavir with a glass of water (i.e., reference condition), complete gastric dissolution was observed. After GI transfer, supersaturation was noticed for a limited amount of time (1.25 h). With respect to the Coca-Cola® condition, complete gastric dissolution was also observed. A delay in gastric emptying, highly likely caused by the caloric content (101 kcal), was responsible for delayed arrival of atazanavir into the upper small intestine, creating a longer time window of supersaturated concentrations in the duodenal segment (3.25 h) compared to the water condition. The longer period of supersaturated concentrations resulted in a slightly higher systemic exposure of atazanavir compared to the condition when atazanavir was taken with a glass of water. A remarkable observation was the creation (when the drug was given in the migrating motor complex (MMC) phase 2) or maintenance (when the drug was given in MMC phase 1) of a quiescent phase for up to 80 min. With respect to the PPI condition, negligible gastric and intestinal concentrations were observed, resulting in minimal systemic exposure for all subjects. It can be concluded that gastric pH and residence time play a pivotal role in the intestinal disposition of atazanavir in order to generate sufficiently high concentrations further down in the intestinal tract for a sufficient period of time, thus creating a beneficial driving force for intestinal absorption.
Collapse
Affiliation(s)
- Bart Hens
- Drug Delivery and Disposition, KU Leuven, Leuven, Belgium
| | - Imke Masuy
- Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven, Leuven, Belgium
| | - Eveline Deloose
- Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven, Leuven, Belgium
| | - Raf Mols
- Drug Delivery and Disposition, KU Leuven, Leuven, Belgium
| | - Jan Tack
- Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven, Leuven, Belgium
| | | |
Collapse
|
12
|
Gusev PA, Andrews KW, Savarala S, Tey PT, Han F, Oh L, Pehrsson PR, Dwyer JT, Betz JM, Kuszak AJ, Costello R, Saldanha LG. Disintegration and Dissolution Testing of Green Tea Dietary Supplements: Application and Evaluation of United States Pharmacopeial Standards. J Pharm Sci 2020; 109:1933-1942. [PMID: 32081719 DOI: 10.1016/j.xphs.2020.02.005] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2019] [Accepted: 02/05/2020] [Indexed: 12/23/2022]
Abstract
Approved performance quality tests are lacking in the United States Pharmacopeia (USP) for dietary supplements (DSs) containing green tea extracts. We evaluated the applicability of USP <2040 > general chapter protocols for disintegration and dissolution testing of botanicals to GT DSs. Of 28 single-ingredient GT DSs tested in 2 to 4 lots, 9 (32.1%) always passed the disintegration test, 8 (28.6%) always failed, and 11 (39.3%) showed inconsistent results. Of 34 multi-ingredient DSs tested in 2 lots, 21 (61.8%) passed and 8 (23.5%) failed in both lots, and 5 (14.7%) exhibited inconsistent performance. When stronger destructive forces were applied (disk added), all of the capsules that had failed initially, but not the tablets, passed. In dissolution testing, for the release of epigallocatechin-3-gallate (EGCG), only 6 of 20 single-ingredient DSs passed. Unexpectedly, with the addition of pepsin (prescribed by USP), only one additional DS passed. These results raise concerns that EGCG was not released properly from GT DS dosage forms. However, the general USP protocols may be inadequate for this botanical. More biorelevant destructive forces may be needed to break down capsules and tablets strengthened by the EGCG's interaction with shell material and to overcome the inhibition of digestive enzymes by EGCG.
Collapse
Affiliation(s)
- Pavel A Gusev
- Methods and Application of Food Composition Laboratory, Beltsville Human Nutrition Research Center, Agricultural Research Service, Department of Agriculture, Beltsville, Maryland 20705.
| | - Karen W Andrews
- Methods and Application of Food Composition Laboratory, Beltsville Human Nutrition Research Center, Agricultural Research Service, Department of Agriculture, Beltsville, Maryland 20705
| | - Sushma Savarala
- Methods and Application of Food Composition Laboratory, Beltsville Human Nutrition Research Center, Agricultural Research Service, Department of Agriculture, Beltsville, Maryland 20705
| | - Phuong-Tan Tey
- Methods and Application of Food Composition Laboratory, Beltsville Human Nutrition Research Center, Agricultural Research Service, Department of Agriculture, Beltsville, Maryland 20705
| | - Fei Han
- Methods and Application of Food Composition Laboratory, Beltsville Human Nutrition Research Center, Agricultural Research Service, Department of Agriculture, Beltsville, Maryland 20705
| | - Laura Oh
- Methods and Application of Food Composition Laboratory, Beltsville Human Nutrition Research Center, Agricultural Research Service, Department of Agriculture, Beltsville, Maryland 20705
| | - Pamela R Pehrsson
- Methods and Application of Food Composition Laboratory, Beltsville Human Nutrition Research Center, Agricultural Research Service, Department of Agriculture, Beltsville, Maryland 20705
| | - Johanna T Dwyer
- Office of Dietary Supplements, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20814
| | - Joseph M Betz
- Office of Dietary Supplements, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20814
| | - Adam J Kuszak
- Office of Dietary Supplements, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20814
| | - Rebecca Costello
- Office of Dietary Supplements, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20814
| | - Leila G Saldanha
- Office of Dietary Supplements, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20814
| |
Collapse
|
13
|
Simulated migrating motor complex and its impact on the release properties of hydrophilic matrix systems. J Drug Deliv Sci Technol 2020. [DOI: 10.1016/j.jddst.2019.101338] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
14
|
The influence of different mechanical stress on the release properties of HPMC matrix tablets in sucrose-NaCl media. J Drug Deliv Sci Technol 2019. [DOI: 10.1016/j.jddst.2019.101246] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
15
|
Krause J, Bogdahn M, Schneider F, Koziolek M, Weitschies W. Design and characterization of a novel 3D printed pressure-controlled drug delivery system. Eur J Pharm Sci 2019; 140:105060. [DOI: 10.1016/j.ejps.2019.105060] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2018] [Revised: 07/17/2019] [Accepted: 08/29/2019] [Indexed: 12/18/2022]
|
16
|
Schick P, Sager M, Wegner F, Wiedmann M, Schapperer E, Weitschies W, Koziolek M. Application of the GastroDuo as an in Vitro Dissolution Tool To Simulate the Gastric Emptying of the Postprandial Stomach. Mol Pharm 2019; 16:4651-4660. [DOI: 10.1021/acs.molpharmaceut.9b00799] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Affiliation(s)
- Philipp Schick
- Department of Biopharmaceutics and Pharmaceutical Technology, Center of Drug Absorption and Transport, University of Greifswald, D-17487 Greifswald, Germany
| | - Maximilian Sager
- Department of Biopharmaceutics and Pharmaceutical Technology, Center of Drug Absorption and Transport, University of Greifswald, D-17487 Greifswald, Germany
| | - Franziska Wegner
- Department of Biopharmaceutics and Pharmaceutical Technology, Center of Drug Absorption and Transport, University of Greifswald, D-17487 Greifswald, Germany
| | | | | | - Werner Weitschies
- Department of Biopharmaceutics and Pharmaceutical Technology, Center of Drug Absorption and Transport, University of Greifswald, D-17487 Greifswald, Germany
| | - Mirko Koziolek
- Department of Biopharmaceutics and Pharmaceutical Technology, Center of Drug Absorption and Transport, University of Greifswald, D-17487 Greifswald, Germany
| |
Collapse
|
17
|
Butler J, Hens B, Vertzoni M, Brouwers J, Berben P, Dressman J, Andreas CJ, Schaefer KJ, Mann J, McAllister M, Jamei M, Kostewicz E, Kesisoglou F, Langguth P, Minekus M, Müllertz A, Schilderink R, Koziolek M, Jedamzik P, Weitschies W, Reppas C, Augustijns P. In vitro models for the prediction of in vivo performance of oral dosage forms: Recent progress from partnership through the IMI OrBiTo collaboration. Eur J Pharm Biopharm 2019; 136:70-83. [DOI: 10.1016/j.ejpb.2018.12.010] [Citation(s) in RCA: 70] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2018] [Accepted: 12/19/2018] [Indexed: 02/08/2023]
|
18
|
Jede C, Wagner C, Kubas H, Weber C, Weigandt M, Koziolek M, Weitschies W. Automated small-scale in vitro transfer model as screening tool for the prediction of in vivo-dissolution and precipitation of poorly solubles. Int J Pharm 2019; 556:150-158. [PMID: 30553006 DOI: 10.1016/j.ijpharm.2018.12.013] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2018] [Revised: 11/30/2018] [Accepted: 12/01/2018] [Indexed: 12/22/2022]
Abstract
Precipitation testing, especially for weakly basic APIs, represents a key parameter in drug substance characterization during early development stages, where the amount of API available is limited. Therefore, it was the aim of this study to develop an automated small-scale in vitro transfer model to characterize the supersaturation and precipitation behavior of two poorly water-soluble drugs. Following automation and scale-down of the standard transfer model, the developed small-scale model was used to assess the impact of gastrointestinal variability, i.e. gastric pH, gastric emptying, and gastrointestinal fluid volumes, on supersaturation and precipitation of two weakly basic model compounds, ketoconazole and a new chemical entity from the research laboratories of Merck KGaA, MSC-A. The experiments revealed that variations in gastrointestinal parameters affected the in vitro behavior of ketoconazole, but not of MSC-A. Elevated gastric pH, as it can result from co-medication with acid-reducing drugs, resulted in lower degrees of supersaturation for both substances. This result is in agreement with the observation that the oral bioavailability of ketoconazole is lowered when proton pump inhibitors are co-administered. The small-scale transfer model presented herein represents a valuable in vitro tool to assess the risk of drug precipitation, additionally covering a broad range of gastrointestinal parameters.
Collapse
Affiliation(s)
- Christian Jede
- Institute of Pharmacy, Department of Biopharmaceutics and Pharmaceutical Technology, University of Greifswald, Felix-Hausdorff-Strasse 3, 17489 Greifswald, Germany; Pharmaceutical Technologies, Chemical and Pharmaceutical Development, Merck KGaA, Frankfurter Strasse 250, 64293 Darmstadt, Germany
| | - Christian Wagner
- Pharmaceutical Technologies, Chemical and Pharmaceutical Development, Merck KGaA, Frankfurter Strasse 250, 64293 Darmstadt, Germany
| | - Holger Kubas
- Pharmaceutical Technologies, Chemical and Pharmaceutical Development, Merck KGaA, Frankfurter Strasse 250, 64293 Darmstadt, Germany
| | - Christian Weber
- Project and Dossier Leadership, Chemical and Pharmaceutical Development, Merck KGaA, Frankfurter Strasse 250, 64293 Darmstadt, Germany
| | - Markus Weigandt
- Pharmaceutical Technologies, Chemical and Pharmaceutical Development, Merck KGaA, Frankfurter Strasse 250, 64293 Darmstadt, Germany
| | - Mirko Koziolek
- Institute of Pharmacy, Department of Biopharmaceutics and Pharmaceutical Technology, University of Greifswald, Felix-Hausdorff-Strasse 3, 17489 Greifswald, Germany
| | - Werner Weitschies
- Institute of Pharmacy, Department of Biopharmaceutics and Pharmaceutical Technology, University of Greifswald, Felix-Hausdorff-Strasse 3, 17489 Greifswald, Germany.
| |
Collapse
|
19
|
Schneider F, Hoppe M, Koziolek M, Weitschies W. Influence of Postprandial Intragastric Pressures on Drug Release from Gastroretentive Dosage Forms. AAPS PharmSciTech 2018; 19:2843-2850. [PMID: 29845498 DOI: 10.1208/s12249-018-1022-3] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2018] [Accepted: 04/13/2018] [Indexed: 12/13/2022] Open
Abstract
Despite extensive research in the field of gastroretentive dosage forms, this "holy grail" of oral drug delivery yet remained an unmet goal. Especially under fasting conditions, the reproducible retention of dosage forms in the stomach seems to be an impossible task. This is why such systems are often advised to be taken together with food. But also the postprandial motility can contribute significantly to the failure of gastroretentive dosage forms. To investigate the influence of postprandial pressure conditions on drug release from such systems, we used a novel in vitro dissolution tool, the dissolution stress test device. With the aid of this device, we simulated three different intragastric pressure profiles that may occur after postprandial intake. These transit scenarios were based on recently obtained, postprandial SmartPill® data. The tested systems, Glumetza® 1000 and Madopar® HBS 125, are marketed dosage forms that are based on different approaches to achieve proper gastric retention. All three transit scenarios revealed a highly pressure-sensitive drug release behavior, for both drugs. For Madopar® HBS 125, nearly complete drug release was observed even after early occurring pressures. Glumetza® 1000 seemed to be more resistant to these, most likely due to incomplete wetting of the system. On the contrary to these findings, data from standard dissolution tests using the paddle apparatus displayed controlled drug release for both systems for about 6 h. Based on these results, it can be doubted that established gastroretentive systems stay intact over a longer period of time, even under postprandial conditions.
Collapse
|
20
|
Koziolek M, Kostewicz E, Vertzoni M. Physiological Considerations and In Vitro Strategies for Evaluating the Influence of Food on Drug Release from Extended-Release Formulations. AAPS PharmSciTech 2018; 19:2885-2897. [PMID: 30155808 DOI: 10.1208/s12249-018-1159-0] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2018] [Accepted: 08/18/2018] [Indexed: 02/08/2023] Open
Abstract
Food effects on oral drug bioavailability are a consequence of the complex interplay between drug, formulation and human gastrointestinal (GI) physiology. Accordingly, the prediction of the direction and the extent of food effects is often difficult. With respect to novel formulations, biorelevant in vitro methods can be extremely powerful tools to simulate the effect of food-induced changes on the physiological GI conditions on drug release and absorption. However, the selection of suitable in vitro methods should be based on a thorough understanding not only of human GI physiology but also of the drug and formulation properties. This review focuses on in vitro methods that can be applied to evaluate the effect of food intake on drug release from extended release (ER) products during preclinical formulation development. With the aid of different examples, it will be demonstrated that the combined and targeted use of various biorelevant in vitro methods can be extremely useful for understanding drug release from ER products in the fed state and to be able to forecast formulation-associated risks such as dose dumping in early stages of formulation development.
Collapse
|
21
|
Paixão P, Bermejo M, Hens B, Tsume Y, Dickens J, Shedden K, Salehi N, Koenigsknecht MJ, Baker JR, Hasler WL, Lionberger R, Fan J, Wysocki J, Wen B, Lee A, Frances A, Amidon GE, Yu A, Benninghoff G, Löbenberg R, Talattof A, Sun D, Amidon GL. Gastric emptying and intestinal appearance of nonabsorbable drugs phenol red and paromomycin in human subjects: A multi-compartment stomach approach. Eur J Pharm Biopharm 2018; 129:162-174. [DOI: 10.1016/j.ejpb.2018.05.033] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2018] [Revised: 05/21/2018] [Accepted: 05/28/2018] [Indexed: 10/16/2022]
|
22
|
Hribar M, Jakasanovski O, Trontelj J, Grabnar I, Legen I. Determining The Pressure-Generating Capacity of The Classical and Alternative In Vitro Dissolution Methods Using a Wireless Motility Capsule. J Pharm Innov 2018. [DOI: 10.1007/s12247-018-9317-1] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/03/2023]
|